德孚在中国

9 7 8 1 6

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

更正启事 — PUMA 调节奥希替尼 (osimertinib) 在结肠癌细胞中的抗癌作用

 

Authors Guo L, Huang S, Wang X

Received 11 April 2017

Accepted for publication 15 August 2017

Published 3 November 2017 Volume 2017:10 Pages 5281—5288

DOI https://doi.org/10.2147/OTT.S139382

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Abstract: Osimertinib, an irreversible EGFR/HER2 inhibitor, has been found to be effective in the cancer cell with EGFR gene mutations in preclinical lung cancer models. However, the effect of osimertinib in colorectal cancer (CRC) cells is unclear. In the present study, we investigated how osimertinib suppresses CRC cells growth and potentiates effects of other chemotherapeutic drugs. We found that p73-mediated osimertinib-induced p53 upregulated modulator of apoptosis (PUMA) expression irrespective of p53 status following PI3K/AKT pathway inhibition in CRC cells. Furthermore, PUMA is required for osimertinib-induced apoptosis. In addition, osimertinib also synergized with 5-FU to induce significant apoptosis via PUMA in CRC cells. These results demonstrated a critical role of PUMA in mediating the anticancer effects of osimertinib and suggest that PUMA induction can be used as an indicator of osimertinib sensitivity.
Keywords: PUMA, osimertinib, apoptosis, p73, CRC



* 作者的正确隶属单位应该是： 

 

“1Department of Pathology, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, 2Department of Oncology, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China”

 

请点击这里查看详细更正启事








Download Article[PDF]